Hansa Biopharma AB (OSTO:HNSA) ROCE %: -65.88% (As of Mar. 2026)


OSTO:HNSA Hansa Biopharma AB OSTO:HNSA
49 GF Score
Price kr33.10
GF Value kr24.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB ROCE %?

Hansa Biopharma AB OSTO:HNSA -1.25% 49 ROCE % is -65.88% as of Mar. 2026. GuruFocus rates OSTO:HNSA with a GF Score™ of 49/100 and a GF Value™ of kr24.55 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hansa Biopharma AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -65.88%.

Hansa Biopharma AB  (OSTO:HNSA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hansa Biopharma AB ROCE % Related Terms

Hansa Biopharma AB ROCE % Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB ROCE % Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.64 -50.02 -68.43 -107.91 -63.01

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.84 -153.07 -149.15 -74.28 -65.88
OSTO:HNSA
49GF Score
Hansa Biopharma AB OSTO:HNSA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB ROCE % Calculation

Hansa Biopharma AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-409.91/( ( (800.642 - 255.687) + (1166.767 - 410.659) )/ 2 )
=-409.91/( (544.955+756.108)/ 2 )
=-409.91/650.5315
=-63.01 %

Hansa Biopharma AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-559.804/( ( (1166.767 - 410.659) + (1162.191 - 218.844) )/ 2 )
=-559.804/( ( 756.108 + 943.347 )/ 2 )
=-559.804/849.7275
=-65.88 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -65.88% mean?
Hansa Biopharma AB (OSTO:HNSA) has a ROCE % of -65.88% as of Mar. 2026.
Is Hansa Biopharma AB's ROCE % too high?
Hansa Biopharma AB's current ROCE % is -65.88%. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's ROCE % compare to VRTX and REGN?
Hansa Biopharma AB's ROCE % of -65.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Hansa Biopharma AB's current ROCE % is -65.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.55, compared to a current price of kr33.10 — trading 34.8% above its estimated fair value. The current ROCE % is -65.88%. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current ROCE % is -65.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr33.10 is trading 34.8% above its estimated GF Value™ of kr24.55. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:HNSA:

  • ROCE %: -65.88%
  • GF Value™: kr24.55 vs. price of kr33.10 (34.8% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score

Get the complete analysis for OSTO:HNSA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr33.10
Price
kr24.55
GF Value